Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TCR-transduced T cells · 1 trial · 1 indication
Severity of adverse events using CTCAE version 5.0
| Arm | Type | Description |
|---|---|---|
| CDX-1140 + TCR-T + Pembro | EXPERIMENTAL | Patients will receive CDX-1440, TCR-T, and pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| TCR-transduced T cells | BIOLOGICAL | TSA-reactive TCR-engineered T cells |
| CDX-1140 | DRUG | Recombinant fully human IgG2κ monoclonal antibody |
| Pembrolizumab | DRUG | Humanized immunoglobulin G4 (IgG4) monoclonal antibody |
Inclusion Criteria: 1. Patients 18 years and older with metastatic or locoregionally advanced epithelial cancers, that are considered incurable. 2. Confirmation by Tran Laboratory of neoantigen-reactive TCR(s) suitable for TCR-gene therapy. 3. Eastern Cooperative Oncology Group (ECOG) performance s...
TCR-transduced T cells is an investigational cell therapy being studied for the treatment of malignant epithelial neoplasms, a type of cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA. The therapy is being evaluated in a single active clinical trial in the United States.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is developing TCR-transduced T cells. The company is conducting a Phase 1 clinical trial of this investigational therapy for malignant epithelial neoplasms. The trial is currently active but not recruiting participants.
TCR-transduced T cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to study the safety and feasibility of this personalized T-cell receptor gene-engineered T cell therapy.
TCR-transduced T cells is being studied in one clinical trial, NCT05349890, titled 'Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)'. This Phase 1 trial is active but not recruiting, with an enrollment of 1 participant, and is being conducted in the United States.
Yes, TCR-transduced T cells is also referred to as TCR-T, as indicated in the clinical trial title. The therapy involves the adoptive transfer of T cells that have been gene-engineered to express a specific T-cell receptor. This personalized approach is being evaluated for malignant epithelial neoplasms.